The short version.
Jet lag is a misalignment problem. Your suprachiasmatic nucleus is on home time; your liver, gut, and peripheral tissues are catching up at different speeds. Light exposure and meal timing are the dominant tools to re-anchor it. Sleep, hydration, and avoiding alcohol matter. NAD+ is downstream of all of that, but it sits at an interesting biochemical intersection.
NAD+ (nicotinamide adenine dinucleotide) is a cofactor in mitochondrial energy production and a substrate for sirtuins — including SIRT1 and SIRT3, which are involved in circadian rhythm regulation. The connection between cellular NAD+ levels and the molecular clock (CLOCK/BMAL1) has been characterized in animal models. Whether exogenous NAD+ accelerates circadian re-alignment in human travelers is a different question, and one without strong randomized data.
What the literature actually says.
Most NAD+ research in humans has focused on aging, mitochondrial dysfunction, and metabolic disease — not jet lag specifically. Studies of NAD+ precursors (nicotinamide riboside, NMN) have shown they can elevate blood NAD+ levels in humans, but translating that to a measurable circadian or fatigue benefit during travel is a leap the literature hasn't fully made.
The animal work is suggestive: in mice, manipulating NAD+/SIRT1 alters circadian gene expression and shifts behavioral rhythms. In humans, the case for using NAD+ during international travel is mostly extrapolation plus subjective user reports — useful information, but not the same as a controlled trial.
The honest framing: if you're chasing a recovery edge after long-haul travel and you're already doing the basics — light exposure, melatonin if appropriate, smart meal timing — NAD+ is a plausible adjunct. It's not a circadian shortcut.
NAD+ is downstream of light exposure and meal timing. Treat it as an adjunct, not a circadian shortcut.
Why oversight matters.
The internet sells almost any peptide as research chemicals — vials with disclaimers, no prescription, no provider, no follow-up. The risk isn't theoretical. Sterility, peptide identity, peptide content, and contamination all vary widely between gray-market vendors. The FDA has been explicit that compounded drugs aren't FDA-approved, and that research-only labels don't protect consumers when products end up in human use.
Oversight isn't a bureaucratic checkbox. It's a U.S.-licensed prescriber who reviews your history before prescribing, a 503A compounding pharmacy that sources active pharmaceutical ingredient and prepares the medication under USP 797 sterile standards, and a follow-up cadence that lets someone catch a problem before it becomes a worse one.
How Boswell handles this.
Boswell pairs you with a U.S.-licensed physician for the intake. They review your goals, medications, history, and any contraindications before prescribing. If a protocol isn't appropriate, you don't get it. If it is, the prescription goes to a 503A compounding pharmacy that prepares the medication under sterile compounding standards, labels it for you specifically, and ships it directly.
Refills aren't automatic — they involve a check-in. The point isn't to gate access; it's to keep someone clinical in the loop while you're on therapy. How Boswell works →
Questions worth asking your provider.
- Given my travel pattern, does NAD+ make sense as a recurring tool or a one-off?
- What's the realistic expectation — energy / cognition / sleep — and over what timeframe?
- Should I prioritize light exposure and melatonin protocols before adding NAD+?
- Are there labs (B-vitamin status, methylation) worth checking first?
- How do you think about route of delivery (subq vs IV) for travel use?
Sources